NIP
VYNT

Nicholas Investment Partners’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Nicholas Investment Partners’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-110
Closed -$334K – 326
2013
Q3 		$334K Buy
+110
New +$188K 0.03% 285

Other funds holding VYNT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sterneck Capital Management Kansas City, Missouri $223M AUM 17.15% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.45B AUM 5.8% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $1.91B AUM 24.37% 1-Year Est. Return

Nicholas Investment Partners's VYNT Position: Q4 2013 in Review

Nicholas Investment Partners sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2013, closing a stake of 110 shares — an estimated $334K sold.

Nicholas Investment Partners first reported a position in VYNT in Q3 2013 and held it in 1 quarter. The position peaked at $334K in Q3 2013. 29 funds tracked by Wall St. Rank hold VYNT as of Q4 2013.

  • Nicholas Investment Partners reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Nicholas Investment Partners sold 110 Vyant Bio, Inc. Common Stock shares in Q4 2013, an estimated $334K.
  • Nicholas Investment Partners first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 1 quarter.
  • Nicholas Investment Partners's Vyant Bio, Inc. Common Stock position peaked at $334K in Q3 2013.
  • 29 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2013.

Based on Nicholas Investment Partners's 13F filing for Q4 2013, filed 13 Feb 2014.